Concentration of 25(OH)D3 and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study;Stężenie 25(OH)D3 i gospodarka wapniowo-fosforanowa u chorych na postać nawracająco-zwalniającą stwardnienia rozsianego. Doniesienie wstępne

Neurologia i Neurochirurgia Polska

Volumn 47, Issue 2, 2013, Pages 126-130

  Kubicka, Katarzyna ^a   Pierzchała, Krystyna ^b  

^a Samodzielny Szpital Kliniczny w Zabrzu   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Dietary supplements; Multiple sclerosis

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIFEDIOL; CALCIUM ION; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PHOSPHATE METABOLISM; PILOT STUDY;

EID: 84876889397     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2013.34730     Document Type: Article

References (18)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
2. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 254: 942-955.
3. Pierzchała K. Rola czynników środowiskowych w patogenezie stwardnienia rozsianego. Wiad Lek 2009; 62: 37-41.
4. Pugliatti M., Riise T., Sotgiu M.A., et al. Increasing incidence of multiple sclerosis in the province of Sassari. Neuroepidemiology 2005; 25: 129-134.
5. Ebers G.C. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252 (Suppl3): III15-III21.
6. Ebers G.C. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277.
7. van der Mei I.A.F., Ponsonby A.L., Blizzard L., et al. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001; 20: 168-174.
8. Van Amerongen B.M., Dijkstra C. D, Lips P., et al. Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr 2004; 58: 1095-1109.
9. Hayes C.E., Acheson E. A unifying multiple sclerosis etiology linking virus infection sunlight, and vitamin D, through viral interleukin 10. Med Hypotheses 2008; 71: 85-90.
10. Correale J., Ysrraelit M., Gaitan M. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132: 1146-1160.
11. Charzewska J. Sprawy nauki. Biuletyn Ministerstwa Nauki i Szkolnictwa Wyższego 2005; 1-4.
12. Nieves J., Cosman F., Herbert J., et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687-1692.
13. Cendrowski W. Neuroepidemiologia kliniczna. Volumed, Wrocław 1997.
14. Goldberg P. Multiple sclerosis. Vitamin D and calcium as determinants of prevalence. Part 1: Sunlight, dietary factors and epidemiology. Int J Environ Stud 1974; 6: 19-27.
15. van der Mei I.A.F., Ponsonby A.L., Dwyer T., et al. Past exposure to sun, skin, phenotype and risk of multiple sclerosis. Casecontrol study. BMJ 2003; 327: 316-321.
16. Napiórkowska L., Budlewski T., Jakubas-Kwiatkowska W., et al. Prevalence of low serum vitamin D concentration in an urban population of elderly women living in Poland. Pol Arch Med Wewn 2009; 119: 699-703.
17. Kuchuk N.O., van Schoor N.M., Pluijm S.M., et al. Vitamin D status, parathyroid function, bone turnover and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009; 24: 693-701.
18. Schwarz S., Leweling H. Multiple sclerosis and nutrition. Mult Scler 2005; 11: 24-32.